Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
Technology
History
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/8d/b8/0f/8db80f81-2247-4672-914d-289f9cb6f61b/mza_3544939216694081436.jpg/600x600bb.jpg
The Long Run with Luke Timmerman
Timmerman Report
186 episodes
1 week ago
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Show more...
Science
RSS
All content for The Long Run with Luke Timmerman is the property of Timmerman Report and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Show more...
Science
Episodes (20/186)
The Long Run with Luke Timmerman
Ep188: Art Krieg on Innate Immune System Activators for Cancer
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Show more...
1 week ago
1 hour 9 minutes 5 seconds

The Long Run with Luke Timmerman
Ep187: Eric Fischer on Creating a New Class of Medicines
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.
Show more...
3 weeks ago
1 hour 5 minutes 48 seconds

The Long Run with Luke Timmerman
Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope
Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.
Show more...
1 month ago
1 hour 2 minutes 33 seconds

The Long Run with Luke Timmerman
Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale
Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.
Show more...
1 month ago
1 hour 5 minutes 47 seconds

The Long Run with Luke Timmerman
Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies
Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.
Show more...
2 months ago
1 hour 50 minutes 23 seconds

The Long Run with Luke Timmerman
Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors
Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.
Show more...
3 months ago
56 minutes 23 seconds

The Long Run with Luke Timmerman
Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science
Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.
Show more...
3 months ago
1 hour 1 minute 18 seconds

The Long Run with Luke Timmerman
Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer
Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.
Show more...
4 months ago
57 minutes 18 seconds

The Long Run with Luke Timmerman
Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA
John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.
Show more...
4 months ago
1 hour 10 minutes 45 seconds

The Long Run with Luke Timmerman
Ep179: Ethan Weiss & Josh Lehrer on a New Idea for Cardiovascular Disease & Diabetes
Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes.
Show more...
5 months ago
1 hour 3 minutes 25 seconds

The Long Run with Luke Timmerman
Ep178: Peyton Greenside on ML-Guided Biologics Discovery
Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.
Show more...
5 months ago
1 hour 2 minutes 56 seconds

The Long Run with Luke Timmerman
Ep177: Kevin Parker on Finding Cancer Drug Targets
Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.
Show more...
6 months ago
58 minutes 13 seconds

The Long Run with Luke Timmerman
Ep176: David Roblin on Building a TechBio Company
David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.
Show more...
7 months ago
1 hour 19 minutes 28 seconds

The Long Run with Luke Timmerman
Ep175: Andy Scharenberg on in vivo CAR-T cell therapies
Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.
Show more...
7 months ago
1 hour 10 minutes 46 seconds

The Long Run with Luke Timmerman
Ep174: Najat Khan on the TechBio Movement
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.
Show more...
8 months ago
1 hour 7 minutes 16 seconds

The Long Run with Luke Timmerman
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.
Show more...
8 months ago
57 minutes 56 seconds

The Long Run with Luke Timmerman
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
Show more...
9 months ago
1 hour 20 minutes 53 seconds

The Long Run with Luke Timmerman
Ep171: Ram Aiyar on RNA Editing Medicines
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.
Show more...
9 months ago
1 hour 1 minute 48 seconds

The Long Run with Luke Timmerman
Ep170: David Schenkein on Investing in the Future of Biotech
David Schenkein, general partner at GV, on investing in the future of biotech.
Show more...
10 months ago
59 minutes 52 seconds

The Long Run with Luke Timmerman
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
Show more...
11 months ago
1 hour 2 minutes 28 seconds

The Long Run with Luke Timmerman
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.